Immunocore Holdings Ltd Asset Resilience Ratio
Immunocore Holdings Ltd asset resilience ratio. Immunocore Holdings Ltd (IMCR) has an Asset Resilience Ratio of 35.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMCR days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Immunocore Holdings Ltd (2016–2025)
Asset resilience ratio of Immunocore Holdings Ltd from 2016 to 2025. This chart shows how Immunocore Holdings Ltd's Asset Resilience Ratio has changed over time. Read IMCR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Immunocore Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Immunocore Holdings Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $395.29 Million | 35.31% |
| Total Liquid Assets | $395.29 Million | 35.31% |
Asset Resilience Insights
- Very High Liquidity: Immunocore Holdings Ltd maintains exceptional liquid asset reserves at 35.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immunocore Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Immunocore Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Immunocore Holdings Ltd Asset Resilience Ratio by Year (2016–2025)
Immunocore Holdings Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Immunocore Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.15% | $396.44 Million | $1.07 Billion | +1.02pp |
| 2024-12-31 | 36.12% | $364.64 Million | $1.01 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $597.00 Million | -- |
| 2017-12-31 | 17.45% | $34.55 Million | $198.04 Million | -1.82pp |
| 2016-12-31 | 19.27% | $42.22 Million | $219.08 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more